Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study. The post Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations appeared first on Investor's Business Daily.
Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.
The post Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
